China’s Role in Insilico Medicine’s $2.5B Agreement with SK Biopharmaceuticals

Key Topics in this News Article:
News Snapshot:

In a groundbreaking development for the biopharmaceutical industry, the Hong Kong-listed AI drug discovery firm Insilico Medicine has clinched a monumental deal worth $2.5 billion with Korea’s SK Biopharmaceuticals. The….. Subscribe for Full Access! Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years! Subscribe! Share this Data

  • This field is for validation purposes and should be left unchanged.
  • Newsletter to Your Inbox

    China intelligence delivered each week!

  • This field is hidden when viewing the form